Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - cyproterone acetate -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; iron oxide yellow; macrogol 400 - treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials).,the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - timolol maleate -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 250 microgram - tablet, uncoated - excipient ingredients: magnesium stearate; rice starch; lactose monohydrate; oxidised maize starch; hydrolysed maize starch - congestive heart failure - sigmaxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. sigmaxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because sigmaxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - sigmaxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 0.0625 microgram - tablet, uncoated - excipient ingredients: lactose monohydrate; rice starch; magnesium stearate; hydrolysed maize starch; povidone; indigo carmine; oxidised maize starch - congestive heart failure - sigmaxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. sigmaxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because sigmaxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - sigmaxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 2 mg - tablet, uncoated - excipient ingredients: sodium benzoate; docusate sodium; maize starch; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate; povidone; microcrystalline cellulose; lactose - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 1 mg - tablet, uncoated - excipient ingredients: indigo carmine; docusate sodium; sodium benzoate; lactose; sodium starch glycollate; povidone; magnesium stearate; maize starch; colloidal anhydrous silica; microcrystalline cellulose - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; maize starch; lactose; povidone; sodium benzoate; magnesium stearate; microcrystalline cellulose; docusate sodium; sodium starch glycollate; colour - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - prednisolone sodium phosphate, quantity: 6.72 mg (equivalent: prednisolone, qty 5 mg) - suppository, moulded - excipient ingredients: hard fat - indications as at 01 jan 1991 : predsol suppositories are indicated for the treatment of haemorrhagic and granular proctitis, post-radiation proctitis and rectal complication of crohn's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - amoxicillin trihydrate -